Neuland Laboratories Ltd share price logo

Neuland Laboratories Ltd

NSE: NEULANDLAB

BSE: 524558

Small Cap

Pharma Sector

₹17285.00

+253.00

(+1.49%)

as on

bell
The current prices are delayed by 15 mins, login to check live prices.

Tech Chart

Neuland Laboratories Stock Performance

as on May 7, 2026 at 9:31 pm IST

  • Day's Low

    Day's High

    ₹17,032.00
    ₹17,500.00
    downward going graph

    1.46%

    Downside

    1.24%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    ₹10,578.00
    ₹19,747.00
    downward going graph

    38.80%

    Downside

    14.24%

    Upside

    downward going graph

Neuland Laboratories share price movements today

Previous Close
₹17,032.00
Open
₹17,032.00
Volume
67.07K
Upper Circuit
₹20,438.00
Lower Circuit
₹13,626.00
Day's Low - High
₹17,032.00 - ₹17,500.00
52 Week Low - High
₹10,578.00 - ₹19,747.00

Neuland Laboratories Historical Returns

1 Month Return
+ 29.27 %
3 Month Return
+ 22.62 %
1 Year Return
+ 40.81 %
3 Year Return
+ 687.86 %
5 Year Return
+ 535.51 %

Neuland Laboratories Fundamentals

as on May 7, 2026 at 4:01 pm IST

Market Cap

₹21,851.87 Cr

Return on Equity (ROE)

14.86

PE Ratio (TTM)

122

Return on capital employed (ROCE)

18.61

Industry PE ratio

43.94

Beta (LTM)

0.85

P/B Ratio

10.27

Dividend Yield

0.1

PEG Ratio

-1.3

Quarterly Earnings Growth YOY

-60.06

EPS (TTM)

201.63

Sector

Pharmaceuticals

Book Value

1181.32

Neuland Laboratories Stock Valuation

as on May 7, 2026 at 4:01 pm IST

Neuland Laboratories in the last 5 years

  • Overview

  • Trends

Lowest (10.19x)

March 30, 2020

Industry (43.94x)

May 6, 2026

Today (122.00x)

May 6, 2026

Highest (122.00x)

May 6, 2026

LowHigh

Today’s Price to Earnings Ratio: 122.00x

Neuland Laboratories Technical Analysis

Track how Neuland Laboratories technical analysis has moved over time to understand its trends.

1 min
5 min
15 min
30 min
1 day
1 week
1 month

Technicals Summary

Bearish

Neutral

Bullish

Bearish

Moving Averages

Bearish

Neutral

Bullish

Bearish

Oscillators

Bearish

Neutral

Bullish

Neutral

Overall

Bearish7
Bullish4
Neutral4

Oscillators

Name

Value

Action

MACD level (12,26)
-11.92
Bullish
CCI (20)
-24.1
Neutral
RSI (14)
51.1
Neutral
Momentum (10)
14
Bearish
ADI (14)
23.75
Neutral
Ultimate Oscillator (7,14,28)
46.46
Neutral

Moving Averages

Name

Value

Action

SMA (20)
17279
Bullish
EMA (20)
17278.8
Bullish
VWMA (20)
17269.91
Bullish
SMA (50)
17303.3
Bearish
EMA (50)
17298.58
Bearish
SMA (200)
17370.72
Bearish
EMA (200)
17329.3
Bearish
KAMA (200)
17313.91
Bearish
DEMA (200)
17355.2
Bearish

Neuland Laboratories Ltd vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Neuland Laboratories with its industry peers.

Company
Analyst View
Market Cap(in ₹ Cr)
5 Year CAGRDebt to Asset Ratio
Net Profit(in ₹ Cr)
Yearly Revenue(in ₹ Cr)
Neuland Laboratories Ltd image
Neuland Laboratories Ltd
BUY21,851.87107.1%0.552601,476
Orchid Pharma Ltd image
Orchid Pharma Ltd
BUY3,355.32-11.62%0.5695921
Gujarat Terce Laboratories Ltd image
Gujarat Terce Laboratories Ltd
NA28.5552.41%0.00-150
Shree Ganesh Biotech India Ltd image
Shree Ganesh Biotech India Ltd
NA24.32-17.96%0.00222
Piramal Pharma Ltd image
Piramal Pharma Ltd
BUY21,957.85-2.61%0.69919,151
See all

Market expectation of Neuland Laboratories Stock

Common consensus of the market based on various publicly available news, publications,brokerage expectation and market data

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Neuland Laboratories Stock’s Investor Sentiment and Interest

Investment in Neuland Laboratories Ltd Shares on INDmoney has grown by 51.27% over the past 30 days, indicating increased transactional activity.

Time period: to

Change:51.27% versus previous 30 day period

Search interest for Neuland Laboratories Ltd Stock has increased by 28% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:28% versus previous 30 day period

Neuland Laboratories Ltd Quarterly Profit & Loss

Figures in Rupees Crores

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Sales
362.99
417.75
392.83
385.01
439.6
310.84
398.03
328.36
292.75
514.27
439.71
Other Income
2.04
3.05
2.1
5.36
25.43
4.33
59.68
7.46
7.86
1.8
8.05
Total Income
365.03
420.8
394.93
390.37
465.03
315.18
457.72
335.82
300.61
516.07
447.76
Expenses
266.07
280.26
271.56
278.09
316.24
248.62
311.43
277.29
258.26
358.73
362.58
Operating Profit
96.92
137.49
121.27
106.92
123.36
62.22
86.6
51.07
34.49
155.54
77.13
Operating Profit Margin %
26.7%
32.91%
30.87%
27.77%
28.06%
20.02%
21.76%
15.55%
11.78%
30.24%
17.54%
Profit Before Interest, Tax and Depreciation
98.96
140.54
123.37
112.27
148.79
66.56
146.28
58.54
42.34
157.35
85.19
Interest
2.21
4.43
3.74
3.61
2.67
1.06
2.22
2.35
4.58
5.37
6.79
Depreciation
13.59
14.51
15.14
16.46
16.28
16.07
16.3
16.89
20.19
22.54
23.92
Profit Before Tax
83.16
121.6
104.49
92.2
129.84
49.43
127.76
39.3
17.57
129.44
54.48
Tax Paid
21.28
32.34
23.09
24.64
31.97
16.58
26.18
11.49
3.67
32.58
13.9
Profit After Tax
61.88
89.25
81.39
67.56
97.87
32.84
101.59
27.81
13.9
96.85
40.57
Total Net profit including share of profit / Loss from associate company
61.88
89.25
81.39
67.56
97.87
32.84
101.59
27.81
13.9
96.85
40.57
EPS
48.23
69.56
63.44
52.66
76.28
25.6
79.18
21.67
10.83
75.49
31.62
Actual EPS
48.23
69.56
63.44
52.66
76.28
25.6
79.18
21.67
10.83
75.49
31.62
Adjusted EPS
48.23
69.56
63.44
52.66
76.28
25.6
79.18
21.67
10.83
75.49
31.62
Diluted EPS
48.23
69.56
63.44
52.66
76.28
25.6
79.18
21.67
10.83
75.49
31.62

Neuland Laboratories Ltd Annual Profit & Loss

Figures in Rupees Crores

Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Sales
527.41
666.83
762.71
936.91
951.08
1,191.2
1,558.58
1,476.84
Other Income
4.53
3.49
3.89
16.1
2.08
9.75
12.54
96.91
Total Income
531.94
670.32
766.6
953.01
953.15
1,200.95
1,571.12
1,573.75
Expenses
476.98
608.46
660.82
790.09
808.46
919.36
1,095.99
1,153.58
Operating Profit
50.43
58.37
101.89
146.82
142.62
271.84
462.59
323.26
Operating Profit Margin %
9.56%
8.75%
13.36%
15.67%
15%
22.82%
29.68%
21.89%
Profit Before Interest, Tax and Depreciation
54.97
61.86
105.78
162.91
144.7
281.59
475.13
420.17
Interest
18.93
15.66
21.57
17.9
13.5
13.07
14
8.3
Depreciation
22.1
25.86
31.28
39.68
49.04
52.78
59.7
65.55
Profit Before Tax
13.94
20.34
52.93
105.33
82.16
215.74
401.43
346.32
Tax Paid
1.87
3.9
36.72
24.71
18.34
52.23
101.36
86.22
Profit After Tax
12.06
16.44
16.21
80.63
63.82
163.52
300.08
260.11
Total Net profit including share of profit / Loss from associate company
12.06
16.44
16.21
80.63
63.82
163.52
300.08
260.11
EPS
10.81
13.06
12.63
62.85
49.74
127.45
233.89
202.74
Actual EPS
10.81
13.06
12.63
62.85
49.74
127.45
233.89
202.74
Adjusted EPS
10.81
13.06
12.63
62.85
49.74
127.45
233.89
202.74
Diluted EPS
10.81
13.06
12.63
62.85
49.74
127.45
233.89
202.74

Neuland Laboratories Ltd Cash Flow

Figures in Rupees Crores

Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Net Cash from Operating Activities
44.83
38.68
11.27
69.91
57.34
189.36
60.39
237.21
261.18
317.38
Cash Flow from Investing Activities
-19.86
-42.12
-116.28
-77.23
-48.6
-84.47
-95.45
-61.09
-149.74
-297.99
Cash Flow from Financing Activities
-23.62
-0.09
104.84
11.99
-5.48
-113.68
37.73
-135.79
-69.28
24.96
Net Cash Flow
1.35
-3.52
-0.16
4.65
3.27
-8.77
2.66
40.32
42.16
44.36

Neuland Laboratories Stock Shareholding Pattern

Numbers in percentages

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Promoters
36.03%
35.97%
32.8%
32.74%
32.72%
32.64%
32.68%
32.68%
32.68%
32.64%
32.63%
32.63%
DII
6.76%
6.99%
6.03%
6.54%
6.39%
6.38%
9.08%
10.97%
11.57%
13.54%
14.71%
15.84%
FII
0%
21.57%
22.69%
24.44%
25.72%
26.46%
23.86%
22.11%
21.69%
20.6%
20.9%
20.46%
Government
0.4%
0.4%
0.4%
0.4%
0.4%
0.4%
0.4%
0.4%
0.4%
0.4%
0%
0%
Public
36.62%
35.07%
38.08%
35.88%
34.76%
34.11%
33.98%
33.84%
33.67%
32.81%
31.76%
31.07%
Total Outstanding Shares
1,28,29,889
1,28,29,889
1,28,29,889
1,28,29,889
1,28,29,889
1,28,29,889
1,28,29,889
1,28,29,889
1,28,29,889
1,28,29,889
1,28,29,889
1,28,29,889
Total Shareholders
25,223
26,824
27,723
28,616
29,077
34,567
39,315
39,333
42,419
44,393
46,187
46,304

Mutual Funds that own Neuland Laboratories Stock

Check out the Mutual Funds with significant holdings in Neuland Laboratories.

Neuland Laboratories Corporate Actions

View detailed summary of the earnings and dividend history of Neuland Laboratories.

  • Neuland Laboratories Ltd Earnings Results

    Neuland Laboratories Ltd’s net profit fell -60.06% since last year same period to ₹40.57Cr in the Q3 2025-2026. On a quarterly growth basis, Neuland Laboratories Ltd has generated -58.11% fall in its net profits since last 3-months.

    Read More about Earnings Results

  • Neuland Laboratories Ltd Dividends May,2025

    In the quarter ending March 2025, Neuland Laboratories Ltd has declared dividend of ₹12.00 per share on 15 May 2025 - translating a dividend yield of 0.07%.

    Read More about Dividends

Indices Featuring Neuland Laboratories Stock

Check stock indices that include Neuland Laboratories.

BSE Healthcare

₹46,393.15

0.35 (▲163.92%)

S&P BSE 250 SmallCap

₹6,939.55

1.07 (▲73.49%)

Nifty Smallcap 250

₹17,409.00

1.02 (▲175.15%)

Nifty Small 100

₹18,695.65

0.87 (▲161.55%)

S&P BSE SmallCap Select

₹8,526.87

1.09 (▲92.28%)

Nifty MidSmallcap 400

₹20,825.60

1.07 (▲221.05%)

S&P BSE 400 MidSmallCap

₹12,414.33

1.02 (▲125.10%)

Nifty Smallcap 50

₹9,168.60

0.92 (▲83.85%)

BSE 500

₹36,333.79

0.34 (▲121.90%)

Nifty 500

₹23,214.00

0.35 (▲80.60%)

Insights on Neuland Laboratories Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 10.39% to 11.35% in Mar 2026 quarter

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, NEULANDLAB has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, NEULANDLAB has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, NEULANDLAB stock has moved up by 13.5%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 32.63% of holdings in Mar 2026 quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 96.85 Cr → 40.57 Cr (in ₹), with an average decrease of 58.1% per quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 31.76% to 31.07% in Mar 2026 quarter

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 20.90% to 20.46% in Mar 2026 quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 516.07 Cr → 447.76 Cr (in ₹), with an average decrease of 13.2% per quarter

About Neuland Laboratories Ltd

Neuland Laboratories NLL, a private limited company founded in 1984, manufactures bulk drugs, such as salbutamol sulphate, terbutaline sulphate, labetalol hydrochloride and ciprofloxacin, which are exported to more than 35 countries. To part finance capacity expansion and diversify its product-mix, NLL made an initial public offering in 1994 for Rs 5.69 crores. The Research & Development has developed a process to manufacture Oflaxacin for Regulatory Markets, and the Pashamylaram unit received USFDA approval for Rantidine Hydrochloride Form. During the years 1992-2000 the company introduced Itraconazole, an antifungal drug, Ipratropium Bromide, an antiasthmatic drug, Mirtrazapine, an antidepressive drug, and Ramipril, a cardiovascular drug, while in 2001 it increased its capacity of Ciprofloxacin and Ranitidine with financial assistance from IDBI of Rs.65 lacs. In 2002, it commenced production of Ramipril and in 2003 of Citalopram Hydrobromide, Pirbuterol Acetate, Levofloxacin and Levetiracetam. Furthermore, Neuland Laboratories Ltd has a subsidiary in Delaware USA and in Japan (2008-2009). Neuland Laboratories NLL is thus well-positioned in the bulk drugs market and is continuously striving to expand its product mix with the help of innovation in research and development.

Revenue: ₹439.71Cr as on December 2025 (Q3 FY26)
Net Profit: ₹40.57Cr as on December 2025 (Q3 FY26)
Listing date: 17 May, 1995
Chairperson Name: D Saharsh Rao
OrganisationNeuland Laboratories Ltd
HeadquartersHyderabad
IndustryPharmaceuticals
CEOD Saharsh Rao
E-voting on sharesClick here to vote

FAQs

What is Neuland Laboratories share price today?

Neuland Laboratories share price today stands at ₹17285 as on at the close of the market. Neuland Laboratories share today touched a day high of ₹17500 and a low of ₹17032.

What is the 52 week high and 52 week low range for Neuland Laboratories share?

Neuland Laboratories touched a 52 week high of ₹19747 and a 52 week low of ₹10578. Neuland Laboratories share price today i.e. is closed at ₹17285, which is -12.47% down from its 52 week high and 63.41% up from its 52 week low.

What is Neuland Laboratories's market capitalisation today?

Neuland Laboratories market capitalisation is ₹21,851.87 Cr as on .

How to buy Neuland Laboratories shares?

To buy Neuland Laboratories shares, you need to follow these steps:

  • Open a Demat account and Trading account on INDmoney
  • Fund your Trading account
  • Search for NEULANDLAB or Neuland Laboratories Ltd on the INDmoney app to check live prices of the stock
  • Click on Buy or SIP to place an order to invest in Neuland Laboratories shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.

What is Neuland Laboratories trading volume today?

Neuland Laboratories trading volume is 67.07K as on . This means that 67.07K shares of Neuland Laboratories were bought and sold on the stock market during today's trading session.